Composition, form of production and packaging
? Tablets vaginal from white to white with a light yellow hue of color, oval.
1 tab.
ascorbic acid 250 mg
Excipients: polymethylsiloxane - 10 mg, lactose monohydrate - 670 mg, hypromellose - 60 mg, magnesium stearate - 10 mg.
6 pcs. - blisters (1) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2015.
PHARMACHOLOGIC EFFECT
Ascorbic acid reduces the pH of the vagina, inhibits the growth of bacteria and helps restore and maintain normal pH and flora of the vagina (Lactobacillus acidophilus, Lactobacillus gasseri).
Thus, with a decrease in the pH of the vagina for several days, there is a pronounced suppression of the growth of anaerobic bacteria, as well as the restoration of normal flora (Lactobacillus acidophilus, Lactobacillus gasseri).
PHARMACOKINETICS
In the systemic circulation is found in a small amount. It is excreted by the kidneys.
INDICATIONS
- Chronic or recurrent vaginitis (bacterial vaginosis, unspecific vaginitis) caused by anaerobic flora (due to the altered pH of the vagina);
- for normalization of the disturbed microflora of the vagina.
DOSING MODE
Applied intravaginally. 1 vaginal tablet is injected into the vagina lying on the back with slightly bent legs 1 time / day in the evening before bedtime.
The course of treatment is 6 days. Repeated courses of treatment are possible. If necessary, the course of treatment can be extended for a longer period.
SIDE EFFECT
Allergic reactions: very rarely (<1/10 000) - hypersensitivity to one of the components of the drug.
Local reactions: rarely (<1/100,? 1/1000) - burning or itching in the vagina, increased mucosal discharge, hyperemia, swelling of the vulva.
The drug is well tolerated.
CONTRAINDICATIONS
Candidiasis vulvovaginitis;
- hypersensitivity to any of the components of the drug.
PREGNANCY AND LACTATION
The use of the drug during pregnancy and during lactation is not contraindicated.
SPECIAL INSTRUCTIONS
The drug does not inhibit the growth of the fungal flora of the vagina.
Interruptions in the use of the drug Vaginorm-C В® in connection with inter-cyclic or menstrual bleeding are not necessary.
Ascorbic acid affects the results of the determination of glucose in the urine, the content of transaminases, lactate dehydrogenase and bilirubin in the blood serum.
Such manifestations as burning and itching can be caused by the presence of concomitant asymptomatic fungal infection. Therefore, with these symptoms, an analysis should be performed to exclude the fungal infection.
OVERDOSE
Cases of overdose are not described.
DRUG INTERACTION
Salicylates stimulate the process of removing ascorbic acid from the body.
Estrogens increase the bioavailability of ascorbic acid.
Ascorbic acid reduces the activity of anticoagulants.
TERMS OF RELEASE FROM PHARMACY
The drug is approved for use as a means of OTC.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored out of reach of children, dry place at a temperature of no higher than 25 В° C. Shelf life - 3 years.
